Analysts suggested the deaths could overshadow the PFS results, and the safety trade-off may make it harder for ADC ...

In a sit-down interview with pharmaphorum, Henar Hevia, EMEA therapeutic lead for oncology and Carolyn Sousa, EMEA strategy ...

The London company, based at the King's Cross life sciences and tech hub and led by former scientists at AstraZeneca, ...

A £600 million tranche of government funding for a key part of the UK's life sciences strategy – expanding the country's ...

AbbVie's antibody-drug conjugate (ADC) Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, with hundreds of women every year expected to be eligible for ...

Walk through an automotive assembly plant, and you'll see a masterclass in precision. Automated lines, zero-waste workflows, ...

Gedatolisib is a PAM pathway inhibitor – combining PI3K and mTOR inhibition in one molecule – and in the VIKTORIA-1 trial was ...

Shares in French biotech Abivax tumbled more than 30% today, after it announced phase 3 data with ulcerative colitis (UC) ...

The Coalition for Epidemic Preparedness Innovations (CEPI) has made $60 million available for clinical trials of vaccines for ...

In the latest part of its plan to cut barriers to cell and gene therapy (CGT) development, the FDA has published draft ...

The SUPPORT+ mobile app, developed by researchers led by Dr Wing-Lok Chan at Hong Kong University, delivers weekly reminders ...

While still in the early stages of development, in vivo CAR-T therapies have generated excitement about their potential as ...